Member Info for Trinityman

https://www.worldometers.info/coronavirus/

Clicking on the link above and selecting the latest 7 day moving average gives 6,788 deaths per day globally.

There are currently 69,287 serious/ critical reported cases.

Up to 40% of these lives could have been saved and those on ICU wards could have a better outcome with the correct medication.

If only....

EUA - Only a matter of time.

Patience = Profits.

ATVB T

Nigel2509 - Re your 12.01
'We may as well tell jokes because nobody knows what will happen with this stock....'

Here you go then:

The AIM market is worse than a divorce, you lose over half your money but still keep the wife.
(Apologies Manifesto).

All I ask is the chance to prove that money can’t make me happy. (Spike Milligan).

Q: How do I find a good small-cap fund manager?
A: Find a good large-cap fund manager, and wait.

Q: How do you make a million dollars in the stock market?
A: Start with two million.

If you're 85% down, you have to smile at some point, may as well start now. :)

ATVB T

gggg21 - re your 11.51:

Many thanks, but the excellent poster Gunto2020 already gave us the 'heads up' yesterday -

Mon 03/03 @ 08.47:

Quality systems manager – started March - Has previous relevant experience at three other companies.

I took a close look at what a QSMs do:

Quality systems managers are responsible for developing the quality strategy and ensuring that manufacturing industries run efficiently. They prepare and conduct plant staff training on quality principles and identify areas to minimize waste and enhance efficiency.

Note the word 'manufacturing'.

Gunto also gave us this link recently - Take a special note of 'Goal 2'.

https://www.niaid.nih.gov/grants-contracts/peruse-pandemic-preparedness-plan

Keep Gunto on your list of posters to take note of, he has a talent for finding nuggets of highly relevant information and also fends off the riff-raff on here in fine style.

Keep up the good work Gunto - much appreciated.

ATVB T

Kevin - Yes, but I think the top line death reduction figure for baricitinib was only around 13% from memory and there were some ongoing safety concerns post discharge.
ATVB T.

I have taken the liberty of re-posting the following from one of the most respected long term posters on this board, as I feel the weight of significance was lost due to the sheer number of ‘dross’ posts during the day.

The post is succinct and to the point and sums up why anyone still holding shares has more than a fighting chance of not just fully recouping losses, but eventually making a decent profit. We are not called long term holders for nothing.

Beforegolf 19.20 Thursday 03/03:

The secondary end points were significantly better than SOC.
Progression to serious illness/death within 35d was 36.3% better
Progression to intubation/death within 35d was 32% better
Progression to Death within 35d was 40.5% better.

Conclusion. It works. Of that there is no doubt. The safety profile alone is immense.

The trial 'failed' for 3 reasons
1. Improved SOC & Vaccinations changed the playing field
2. The trial design was based on the P2 trial and not seriously changed to reflect the new landscape
3. Even though 6 times the size of P2, it was still not powered enough to drive out statistical significance.

NOT because the drug doesn't work, because it obviously does.

The deep dive into the P3 results being undertaken will, I think, drive out some much better and statistically significant results. We just have to wait, patiently.

Good ACTIV2-p2 data and/or better Sprinter analysis will pave the way to a very quick EUA from FDA.

And there will be a Polygon TR-1 tomorrow :-)

Beforegolf was right in regard to the last sentence and I believe the same applies to all of the above.
This is NOT clutching at straws, this is solid analysis in the cold light of day after the dust has settled. Much appreciated by me and I suspect many of the ‘silent majority’ that read this board but prefer not to comment.

The recent panic selling and dramatic 85% drop is a classic example of why company management prefer their shares to be in the hands of institutional investors and not the general public.

As a fundamental investor, I’m asking three questions this evening:

1 Does Synairgen have a treatment that is commercially viable? Yes.

2 Is the drug safe and free from side effects? Yes.

3 Is there any direct competition the can get a similar product to market first? No.

We already know Activ-2 Phase 2 results will be decent, as the ‘Kansas doctor’ virtually told us several months ago, without actually mentioning Synairgen by name.

Hard to believe that before any human testing results were announced the share price was 35p.
Two years later, with clear evidence this treatment works to a degree in both home and hospital settings the share price is now languishing around 24p.

No wonder Polygon are adding, follow the money....

ATVB T

27 posts in under 2 hours - A new record for this board?

If I remember rightly Dactions, you were in the room when RM made his original AJ Bell investment presentation back in 2016.
I genuinely feel for you having been part of this story for so long.

I see the story that broke around 3.40 has contributed to another round of panic selling.
Nervous investors haven't fully digested the contents properly, big thanks to Tommy D and Brighty for providing detailed clarity for those like myself just coming in from work and trying to get our heads round the latest development.

More than ever, we need word from SNG to confirm they are still included on Activ-2 Phase 3 or not.
As it stands, we appear to be tainted by SAB's failure today.
Are we in or out? We need to be told and soon.

ATVB T

TommyD 19 - Re your 16.20:

Joe Walsh 1976 Album 'You Can't Argue With A Sick Mind'.

No surprise my conversation/ thread with Massive Ray with was deleted abruptly today.

Many thanks for your input here over the past week, I know it's a form of talking therapy for you.
I'm sure we'll get something out of this, probably later rather than sooner now though.

ATVB T

Brand - 100% Agree with all of your post, probably the best and most considered summary of events seen on this board over the past week.

I would add that the CEO should speak publicly in the near future, in order to address the real concerns of retail investors and also give the views of the company and institutional investors in light of recent events - That is a significant element of his role and should not be neglected at this difficult time.

ATVB T

(Cont from Below....)

In addition, Synairgen were originally introduced to investors as a broad based respiratory research and development drug company that has now been somewhat hijacked by circumstances into a covid company.

Covid is transient, but COPD is constant. This is what the major pharmas will look towards, as this is where the long-term annual recurring revenues will be made.

I agree with the poster who mentioned a couple of days ago that SNG’s original COPD trial was almost complete (short of 11 patients I think) and suggested that the trial should be quickly finalised, in order to provide more results.

Take a look at the following COPD figures, the numbers are staggering.

In 2018, 156,045 Americans died from COPD, making it the fourth overall leading cause of death behind heart disease, cancer, and accidents and unintentional injuries, or the third disease-related cause of death.

This equates to one death every 3½ minutes. This is just the USA alone.

Chronic Obstructive Pulmonary Disease (COPD) is the third leading cause of death worldwide, causing 3.23 million deaths in 2019.

https://www.lung.org/research/trends-in-lung-disease/copd-trends-brief/copd-mortality
https://www.cdc.gov/dotw/copd/index.html#:~:text=Key%20Facts,1%20death%20every%204%20minutes!
https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd)

I realise all patients wouldn’t be eligible for treatment and many healthcare systems won’t be able to afford Synairgen’s treatment, but these figures show the sheer size of the market into which they could be selling over many decades.

Everything hinges on Activ-2 now, I doubt SNG would have been progressed to phase 3 without good reason, but this is now turning into what one investor on another board calls a ‘champagne or cyanide’ share.
Still a strong hold for me, but I’ll admit I’m no longer relaxed about my substantial investment and I’m definitely losing sleep over this now. Activ-2 results can’t come soon enough.

ATVB T

When the steroids don’t work, take Synterferon.

Wouldn’t it have been better if we had woken up to something similar to this last Monday?

‘Synairgen are pleased to announce the results of our recently completed Phase 3 trial.
We are excited to announce that our new drug is now proven to save the lives of up to 40% of patients that cannot be saved with other conventional treatments in a clinical setting. In addition, our ground breaking treatment will prevent tens of thousands more progressing to severe illness and poor quality of life.

Although the primary endpoints of our phase 3 trial were not met, Synairgen is now perfectly placed to ease the burden of covid in a clinical setting, both medically and financially, at the same time improving outcomes for a significant percentage of covid patients who could not benefit from traditional medicine alone.

In addition, our treatment is one of only a very small percentage of drugs that has now progressed to the USA Activ-2 Phase 3 trial.
As we eagerly await the results from Activ-2 Phase 2, on receipt we envisage urgent talks with the FDA regarding an application for immediate emergency use authority.

We reiterate that our treatment is proven to be safe and patients display no side effects during or post treatment.

The company is also making preparations to finalise our original COPD trial, as we believe our treatment will be effective in relieving symptoms of this and other respiratory illnesses. We will update the market accordingly.’

A more positively worded RNS would have certainly seen a significant drop, but not the jaw dropping 85% we had to endure.

RM certainly has some explaining to do and preferably not to talking head Katie Pilbeam with her pre-arranged scripted questions. I’d prefer a grilling from someone like LSE’s very own Donald Leggett, who isn’t afraid to ask the pertinent questions investors would like answering. I doubt he will be given the opportunity.

When investors lose money they want a scapegoat, but RM isn’t responsible for the design of the recent ‘compromised’ phase 3 trial, that would be science led, so there should be a collective responsibility at Synairgen. However, the CEO is paid to lead, direct and be aware of all aspects. He is the mouthpiece of the company and should provide some clarity of the way forward to investors as we await Activ-2 results.

Using figures taken from ‘The New York Times’ for reference, the current weekly covid death rate in the USA alone is 1,887. This equates to an annual total of circa 98,000. If Synairgen can save approx. 40% = 39,000 lives saved in a 12 month period. This is addition to the tens of thousands who would be saved from progression to severe illness. Bear in mind this is just one country, these are not small numbers. There is still a seriously lucrative commercial opportunity on the table here if Activ-2 P2 give a top line result of 40% or better.

(Cont above....)

I’ve never stayed awake for 48 hours until this week. It took 24 hours to actually process that RNS fully on Monday. I doubt there are many posters who have been more bullish about this company than me over the last few weeks, you can imagine I’m feeling, like you, more than a little beaten up right now.

Had a very difficult conversation with my long suffering wife yesterday about the heavy losses, so fortunate to have her understanding. Truly heart wrenching to hear some of the stories of personal loss, they were so similar to the posts after the Sirius Minerals debacle. Back then a group on the LSE board had to reach out into the real world to find the identity of one individual who posted a suicide message, having gambled his life savings on that share - At least we have been spared that on this occasion.

Looking back and given the evidence provided, I still think we all made the right decision to invest, which sounds as if I’m in denial as we were 85% down on the day. Having unknotted my stomach, started eating again and stopped continually pacing around, I have reassessed and still believe that this drug is commercially viable.

What no one has taken into account in the thousands of posts over the last few days is that inhaled interferon is safe and is well tolerated. This is a massive ‘unique selling point’ that should be highlighted much more in official communications.
I can confirm first hand that corticosteroids have long lasting side effects and I would imagine that the maximum daily life saving doses taken by hospitalised patients over a number of weeks will also have similar effects.

The truth is this share was always going to stand or fall on the results coming out of America, not the UK. This is why I haven’t and won’t be selling a bean until that point.

Sprinter has ensured we won’t be enjoying the profits envisaged by RM in his original presentation back in 2016, but we should at the very least get our money back and then some more modest gains if US results are good. Team USA won’t have let a small UK company complete their flagship phase 2 trial without good reason and Polygon’s recent activity adds to that view. Polygon effectively controlling the company (many thanks to GGGG21 for his contributions, yet again, this eve) does not put the BOD, or in a healthy position.

You may remember, the US are trying to develop the concept of Telemedicine and ‘at home’ treatments. If Activ2 results are positive, then this drugs fits that profile perfectly and we may see some real uplift in the share price, although it's a long, long way back from here.
Anything less and investor sentiment, which is everything on AIM, will take over once more and then more 24 hour horror will unfold.

Big losses on SXX, really massive gains with NCYT, big gains with SNG followed by big losses, desperately hoping AGL comes good in March. AIM – Not good for the soul or blood pressure.

Off to eat some more humble pie and then hopefull

(Cont from below….)

1972 – Beclometasone:

50 years in production and still widely used today. The beclomethasone market was valued at US$2.3 billion in 2016 and sales are growing at an annual rate of 4.9%.

https://dataintelo.com/report/global-beclomethasone-dipropionate-market/

I know many investors struggle to visualise the size of a billion, so using time as a gauge:
One million seconds is approx 11 days ago – One billion seconds ago was 1989. This should concentrate the mind as to what a similar treatment could be worth in 2022.

2022 – ‘Synterferon’:

As Sir David Jack started to wind down his career, Stephen Holgate – Young British research and development immunology scientist – Starts researching a new type of inhaled treatment around 1980 that, unlike steroids that have long-lasting side effects (believe me, they do), utilises a safe, naturally occurring substance produced by the body – Sets up a small British research company – Forges links with GSK – Knighted for his services to respiratory medicine….You know the rest.
I hope you can see where we are going with this…. the parallels are startling and too close to ignore….This is history repeating itself.

50 years since the last ‘game changing’ respiratory treatment – Do you really think you should be wasting brain cells reading ‘why the delay’ posts on here?

The global respiratory inhalers market was estimated to be valued at US$33.41 billion in 2020 and is projected to reach at a market value of US$51.7 billion by 2031.

https://www.globenewswire.com/news-release/2021/06/14/2246720/0/en/Respiratory-Inhalers-Market-will-reach-US-51-7-Billion-by-2031-Visiongain-Research-Inc.html

I appreciate Synairgen’s nebulised treatment cannot be compared to inhalers in financial terms, so can’t be aimed at all patients, but these figures give an indication of the size of the market SNG will be selling into moving forward.

As an individual retail investor, you are perfectly positioned in the right place at the right time to benefit, as you witness the introduction of the next blockbuster respiratory drug to this vast marketplace.
ATVB T.

As we immerse ourselves in the day to day micro-management of this share, it’s worth taking a step back on a day when the stock market is closed to reflect the true significance of what we are holding in our portfolios here. The discovery of what are commonly termed ‘blockbuster’ respiratory drugs are extremely rare events, take a look:

1955 – Prednisone (Tablet)

1968 – Salbutamol (Blue inhaler)

1972 – Beclometasone (Brown ‘preventor’ inhaler)

2022 – ‘Synterferon’ (Nebuliser)

1955 – Prednisone:

The first mass produced tablet using a corticosteroid. The primary function of corticosteroids is to reduce inflammation in body organs and tissue. This tablet had limited effects on the respiratory system (including my own), as it was absorbed by the rest of the body and wasn’t directed straight to the lungs.

When a patient’s symptoms were life threatening, GPs would immediately admit the patient to hospital via ambulance. Patients were given oxygen, given a stronger dose of prednisone and placed under observation (on two separate occasions in my case as a young lad), as there were no other viable alternatives.

David Jack, a young British research and development scientist, saw corticosteroids being used in creams to reduce inflammation on the skin during the 1960s and began research into using this specific type of steroid in inhaled form directly into the lungs, in order to offer quick and effective relief to the respiratory system.

Jack worked for a small British company ‘Allen + Hanburys’ that had been taken over by Glaxo Smith Kline (GSK). He discovered and developed Salbutamol and Beclometasone, both entered commercial production after 20+ years of research, development and testing. David Jack was widely recognised as contributing more to respiratory medicine than any other research scientist in the world and was duly knighted in recognition of his achievements.

On a personal note, to illustrate why these drugs can be described as ‘game changing’, within two years during the 1970’s I went from regularly not being able to find enough oxygen in my lungs to carry myself up twelve stairs to bed without assistance, to representing my school in cross country, rugby and cricket. I am deeply grateful to Sir David, as I would imagine are tens of millions of others around the world. You can probably appreciate why I have more than a passing interest in respiratory medicine.

1968 – Salbutamol:

54 years in production, this is still the most commonly prescribed respiratory ‘reliever’ drug in the world. Over 60 million sold in the USA alone last year. The following chart shows how quickly this figure is rising:

https://www.statista.com/statistics/781622/albuterol-prescriptions-number-in-the-us/

Salbutamol was the 7th most common drug prescribed in the USA last year. Imagine holding shares in a company on the cusp of producing a treatment like this…Hmm.

(Cont above….)

As the tedious daily ‘to and fro’ mind games of the board continues, it’s worth taking a look at the bare bones of share price movements over the last couple of years.

24/04/20 – 62p

10/06/20 – 35p

21/08/20 – 246p

15/02/22 – 175p

A 43% drop in six weeks due to nothing more than investor sentiment and lack of news.

Fast forward another nine weeks and with P2 results the price increases 600%.

Today the share price is down 29% from the 2020 top, again due to the same two factors and also a possible macro event.

Throughout last two years the fundamental reasons for investing have increased as the risks have diminished, to an extent that the risk/ reward ratio makes this a more than compelling investment.

Share price slides like these don’t phase the fundamental LTH investor, but they do affect the confidence levels of those with less resolve, allowing institutional investors to increase their holding.

At this stage of the game don’t you find it incredible that individuals can still be persuaded to part with their shares?

As the American comedian and social commentator George Carlin said, ‘The stock market is weird. One guy sells his shares and another guy buys them and they both think they’re right’.

With each passing February trading day those sat on the fence are picked off one by one. How many ‘there’s something not right’ posts will we have to endure if the wait for P3 results trips over into the 5 week month of March?

Synairgen’s BOD will be expected to provide P3 results with bullet proof accuracy, these results must be watertight and not open to question by rivals with ulterior commercial motives. Make no mistake, this will be a watershed moment for the company and all concerned, so have patience and let the third parties entrusted to deliver results do their job.

Given Synairgen’s policy of delivering results to the highest regulatory standards, I’d estimate the earliest results will be announced will be on the last day of the month 7.00am Monday 28th Feb.

Until then, sit back and wait for RM to light the blue touchpaper again.

ATVB T

Good Morning Manifesto – Re your 11.31:

Take a look at this post from the very savvy ‘Hanoihank’ (sadly no longer posting), who summed up the situation better than most back in October:

‘When you have a company with such immense short term prospects largely owned by a somewhat uninformed private investor shareholder base, who furthermore are liable to sell based on emotion and sentiment and contain a large proportion of 10% traders to boot, it is no surprise that a clear headed and nimble hedge fund can prise the shares out of those hands with relative ease.’

It has to be said that the two public faces of Synairgen, Richard Marsden and Sir Stephen Holgate have played a straight bat with investors from the start and have been totally honest with the information provided. There have been long periods of silence from both, as they only speak when they having something worthwhile to say that could have a material bearing on the share price.

This has left the field wide open for the sly operators to feed drip feed their daily seeds of doubt onto this board.
Investors who concentrate only on fundamental facts and not ‘the daily drivel’ are not phased by months of silence.

This ‘effort’ (if you can call it that) from earlier today was so transparent it’s tragic – I didn’t know whether to laugh or cry.

‘I’ve lost patience with RM but not the product. We need a shareholders league to ease RM out and start getting some SP focus into the firm.I feel RM has no loyalty, interest or awareness of investors... As if they were a means to his ends.... A leg up.....someone now to be ignored.’

At least the previous court jesters on here, ‘Shadowboxer’, ‘Tiger16’ and ‘Eva’ (who I don’t think was either female of Maltese) put in some degree of effort and made us smile now and again – This latest offering is truly pathetic.

Personally I think the, ‘We need/ deserve an update now’ comments show a lack of self-confidence in an individual’s investment decision. Remember why you invested in the first place and trust your initial judgment.

I’d much prefer the BOD to take care of business and spend their time talking to major pharmas and the companies involved in manufacture/ production/ supply chain security/ Phase 3 trial / Phase 3 results and not retail investors right now.
Individual retail holders are courted in the beginning, but always take a back seat as a company develops and matures, this is how AIM works, I don’t have a problem with this.

I Follow the advice given by billionaire precious metals investor Eric Sprott, when asked at an investing conference last year what was the best way of making money in shares he replied simply, ‘Get in early, sit tight and don’t look at the daily share price movements’. Wise words indeed.

ATVB T

....return to some sense of normality at this crucial stage.

ATVB T (Apologies for no paragraphs - don't know why it hasn't formatted correctly)

Many thanks for the positive comments, recommends and bumps regarding last evening’s post – much appreciated and gratifying to see it was well received over on the Reddit board.I noted several posters considered the post ‘rampy’. I would define ramping or deramping as posting either positive or negative views in isolation without any accompanying evidence. I admit to having an extremely positive outlook regarding the prospects of SNG, but generally back this up with supporting evidence, so have never considered myself a ramper in the true sense of the word.I took the decision to return after a long absence at this pivotal time in an effort to pull together all the evidence, including pertinent references by many diligent posters, in an effort to restore some sense of realistic perspective back to these pages, something I hope to continue. I also note several posters have serious concerns over the length of time between publication of P2 and P3 results. I doubt finding over 610 patients at a specific stage of covid development across 17 countries who were willing to participate a trial was as easy as some may imagine.I appreciate watching the share price slide is no fun, especially as most AIM shareholders seem to have an investing timeframe of only 3 – 6 months, selling up and hopping from share to share in an effort to time the next leg up elsewhere correctly. The policy of the BOD of not issuing an RNS unless they have concrete news only increases the anxiety levels in investors with less conviction.Before investing, my main focus was on the career of Sir Stephen Holgate, who began his initial research in 1980, long before forming SNG. Now 75 years old, this will be the culmination of 42 years dedication to respiratory medicine. Do you really think he is interested in rushing out Phase 3 results in the final stages of his career? I doubt the impatience of a handful of individual retail investors will be uppermost in his mind right now. Every aspect of this trial will have been carried out to the highest regulatory standards, no mean feat across 17 countries, the results will have to be absolutely watertight and beyond question when peer reviewed before publication in the Lancet (as per P2). This is the only way we can get this treatment to market. Any mistakes, omissions or inaccuracies and the share price will collapse.For Holgate it won’t be about the money, kudos, ego or recognition. It will be the professional satisfaction of seeing his lifetime’s work come to fruition. One long term poster (I think it was Ghia) commented on Tuesday they found the dubious tactics and constant negative comments made by ‘the usual suspects’ on here insulting, given Holgate’s level of dedication and integrity – I totally agree.For clarity, this morning I requested the moderator permanently remove the main culprit from this board, hoping the board can ret

(Cont from below)....

January 2022 – Partnership with Ashfield – Ashfield Engage is supporting Synairgen as it builds its commercialisation infrastructure for the needs of SNG001, initially in the US, pending completion of pivotal trials and regulatory authorisations. This will include the recruitment of dedicated medical affairs, patient services, commercial and market access teams.
Again, Ashfield are not going to ruin their reputation by taking a hopeful punt on Synairgen’s Phase 3 results. They’re happy to take a piece of the action and the resulting reflected glory when this goes into production.

The infrastructure for this has steadily been put into place behind the scenes during 2021. One of the shortest, but most relevant posts last week came from LTH and respected poster ‘Matml74’, who replied to a query regarding Synairgen’s supply and logistics chain from one of the newer shareholder’s in very succint fashion – a few words that say so much:

Matml74 – 02/02/22:

Aerogen (nebuliser)
Akron INF B
Catalent Fill Finish
Thermofisher Linked to Fill Finish

All from FDA approved sites.

Add into the mix Sir Stephen Holgate’s public declaration confirming, ‘this works…’ made last year and Richard Marsden’s last words on the recent promo video, ‘We are ready to play our part’.

So are we Richard, so are we....

Many thanks to the sleuths on here today for finding the time to keep the board up to date with the new vacancies - very much appreciated.
Fitting then that I would like to bring back into focus one of the most important and fundamental elements when researching a company: the quality and experience of newly appointed employees.

When I bought my first and largest tranche of shares two years ago Synairgen had only 19 employees, since that time I have kept a close watch on recruitment and the two that really caught my eye last year are shown below, their relevant areas and level of expertise take up several pages each, I have condensed the areas that will be of most interest to you in one short paragraph. The significance of these hires was somewhat lost in the usual high volume of daily posts.

March 2021 – Richard Hennings, Chief Commercial Officer: A dynamic pharma entrepreneur with 30 years commercial strategy & operational experience….securing financing & enabling accelerated development. Broad partnering experience, successfully supporting fund raising, joint ventures, mergers, acquisitions, divestments and licensing deals. Diverse organisational experience from top 10 global pharmaceuticals to microcap Biotech start ups.

Oct 2021 – Gareth Walters Ph.D. The newly-created role of Chief Regulatory Officer in preparation for SNG001 regulatory submissions. 30 years+ expertise of global regulatory strategy from preclinical, to marketing authorisation, through to post-approval and commercialisation. Previously, Dr. Walters held various senior regulatory and executive management and Board roles at several pharmaceutical and biotech companies, as well as commercial and clinical positions at Roche. During this time he played a key role in bringing innovative new medicines to the market, including in the US and Europe.

Note the last bit, ‘including the US and Europe’ – I’m hoping you’re joining the dots here, especially after today’s activity.

Can anyone seriously believe that individuals of this calibre and experience would ruin their glowing CVs by joining a tinpot pharma minnow with no product to sell? Of course not, they have joined Synairgen to enhance their already excellent track records by playing key roles in bringing a new high profile drug to the world stage.
These seasoned professionals will have had access to more detailed information than is made available to mere retail shareholders like you and me. This will have been no stab in the dark for them and you can be certain they won’t be hanging on a thread waiting for phase 3 results like some of the more nervous individuals on here.
They will be totally relaxed and fully engaged playing their part in bringing this project to commercial production. If this company is good enough for them, it’s good enough for me – Since phase 2 results were announced this was always and still is a ‘strong buy’ for me.
Cont above....